Petmed Express Inc

Petmed Express Inc(PETS)股票分析

$1.220

+0.041 (+3.39%)收盤時

Loading chart…
最高
1.265
開盤
1.170
成交量加權均價
1.22
成交量
272.24K
市值
86.14M
最低
1.170
成交金額
331.68K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.93

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

AI 分析 of Petmed Express Inc (PETS)

持有

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

分析師評級(5)

買進
2 買進
2 持有
1 賣出
目前: 1.22
最低
—
平均
—
最高
—

Morgan Stanley

2026-09-25

目標價

—

減持

Morgan Stanley

2025-04-17

目標價

$3.2

賣出

Lake Street

2024-08-07

目標價

$3.5

持有

Morgan Stanley

2024-06-12

目標價

$3.5

賣出

Lake Street

2024-06-12

目標價

$7

強烈買進

估值指標

Petmed Express Inc(PETS)目前預期本益比為 16.69,5 年平均預期本益比為 -10.16。

預期本益比

合理
5 年均值 P/E
-10.16
目前P/E
16.69
高估
97.16
低估
-117.48

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
7.78
目前EV/EBITDA
-0.93
高估
14.49
低估
1.06

預期股價營收比

合理
5 年均值 P/S
0.76
目前P/S
0.17
高估
1.35
低估
0.16

Alphio AI 對 PETS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%PETS

$4.12

情境價格

基

基準

基準 · 50%PETS

$3.76

情境價格

悲

悲觀

悲觀 · 25%PETS

$3.08

情境價格

持有 PETS 的大戶

O

Oaktop Capital Management II, L.P.

+ 持有PETS

-13.50%

3個月報酬率

事件時間軸

2026-09-21 (ET)

09:00:00

PetMed Express Appoints Tamar Elkeles as Independent Director

2026-09-17 (ET)

09:00:00

PetMed Express Appoints Jeff Willard as CEO

2026-09-14 (ET)

16:30:00

PetMed Express Appoints Andrew Parry as CTO

2026-07-23 (ET)

08:30:00

PetMed Express Enters $37M Sale-Leaseback Agreement with Investor

2026-06-30 (ET)

10:00:00

PetMed Express Receives $3.00 Acquisition Proposal from SilverCape

資訊

PETS 常見問題 —— 由 Alphio AI 解答

PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).

PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.

5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易